Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction (NASDAQ:IOVA)
· seekingalpha.com
Iovance Biotherapeutics, Inc. delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. Read why IOVA stock is a buy.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...